Narcistatin prodrugs

• US 7,462,609 B2
• Filed: 12/09/2003
• Issued: 12/09/2008
• Est. Priority Date: 12/09/2002
• Status: Expired due to Fees

• Current Assignee: Arizona Board of Regents (University of Arizona)
• Original Assignee: Arizona Board of Regents (University of Arizona)
• Inventors: Pettit, George R., Melody, Noeleen
• Primary Examiner(s): SHIAO, REI TSANG
• Application Number:
  US10/537,968
• Publication Number:
  US 20060135481A1
• Time in Patent Office: 1,827 Days
• Field of Search: 546/23, 546/65, 514/80
• US Class Current: 514/80
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07F 9/65744 condensed with carbocyclic or heterocyclic rings or ring systems

Abstract

The present invention provides prodrugs derived from the sparingly soluble anticancer isocarbostyril narciclasine, a component of various Narcissus species, said prodrugs having potential for use against animal and human cancers. Also disclosed is an efficient procedure for the synthetic conversion of narciclasine to several more soluble cyclic phosphate compounds, including “narcistatin”.

Claims

1. A compound having the following structure:

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier therefore.

3. A method for treating cancer selected from the group consisting of leukemia, pancreatic cancer, breast cancer, central nervous system cancer, lung cancer, colon cancer and prostate cancer, comprising administering to a human subject afflicted with cancer a pharmaceutically effective amount of the compound: